Search clinical trials for: insulin aspart

Total 8138 results

Novo Nordisk A/S

Completed

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

South Africa
Novo Nordisk A/S

Completed

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Sweden, Norway
Novo Nordisk A/S

Completed

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Norway, United Kingdom, Sweden, Finland
Novo Nordisk A/S

Completed

Initiation of Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

France
Novo Nordisk A/S

Completed

Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands (SWITCH)

Diabetes Mellitus, Type 2 | Diabetes

Netherlands
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Novo Nordisk A/S

Completed

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects

Healthy | Diabetes

South Africa
Novo Nordisk A/S

Completed

Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin (SIT2MIX)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of, India, Malaysia, Turkey, Argentina, Greece, Australia, Portugal, Thailand, Brazil
Novo Nordisk A/S

Completed

Comparison of Two Formulations of Biphasic Insulin Aspart 70

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects

Healthy | Diabetes

South Africa
Novo Nordisk A/S

Completed

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Canada
Novo Nordisk A/S

Completed

Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Argentina, Brazil
Novo Nordisk A/S

Completed

Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment (EasyMix)

Diabetes Mellitus, Type 2 | Diabetes

Japan, China
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Netherlands
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Russian Federation, Israel, Croatia, Czech Republic, Slovenia
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Sweden, Malaysia, France, Netherlands, India, Argentina, South Africa, Romania, Former Serbia and Montenegro, Austria, Czech Republic, Philippines, Mexico
Novo Nordisk A/S

Completed

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen (Full STEP™)

Diabetes Mellitus, Type 2 | Diabetes

United States, France, Argentina, Macedonia, The Former Yugoslav Republic of, Slovenia, Canada, Brazil
Novo Nordisk A/S

Completed

A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Investigation of the Response Relationship of NN5401 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S
HNEC TEST

Completed

A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, United Kingdom, Belgium, Norway, Germany, Greece
Novo Nordisk A/S

Completed

An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Macedonia, The Former Yugoslav Republic of
Novo Nordisk A/S

Completed

Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Slovakia
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Levemir® Used as Basal Insulin

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Slovakia
Weill Medical College of Cornell University

Withdrawn

Treatment Targets for Chronic Hypertension in Pregnancy

Hypertension | Proteinuria | Pregnancy Toxemia

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, United Kingdom, France, Netherlands, Finland, Germany, Sweden
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Croatia, Italy, Slovakia, Denmark, Macedonia, The Former Yugoslav Republic of, Norway, Russian Federation, Finland, France, Poland, Greece, Romania, Sweden, Czech Republic, Argentina
Novo Nordisk A/S

Completed

Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark, Croatia, Australia, South Africa, Italy, Sweden
Novo Nordisk A/S

Completed

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, Austria, South Africa
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

India, Macedonia, The Former Yugoslav Republic of, Malaysia, Turkey, Croatia, Bulgaria, Romania, Australia, South Africa, Argentina
Novo Nordisk A/S

Completed

Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, France, Denmark, Sweden, Netherlands, Belgium, Finland, Macedonia, The Former Yugoslav Republic of, Norway, Israel, Spain, Croatia, Slovenia, United Kingdom, Switzerland, Ireland
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Sweden, Finland, France, Norway
Novo Nordisk A/S

Completed

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Spain, Hungary, Mexico, Argentina, Slovakia, Greece, South Africa, Australia
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs

Diabetes Mellitus, Type 2 | Diabetes

Morocco, Tunisia, Algeria, South Africa, Egypt
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes (ACTION)

Diabetes Mellitus, Type 2 | Diabetes

United States

Search clinical trials for: insulin aspart

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations